Seroba Life Sciences led a €21m Series B round in Coave Therapeutics.

Seroba Life Sciences led a €21m Series B round in Coave Therapeutics, a clinical stage biotechnology company focused on developing life changing gene therapies, with participation from Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne. "I am very pleased to have successfully completed this fundraising and welcome the new investors alongside our existing investors. Coave Therapeutics is at an exciting point in its development as we look to develop and generate value from our enhanced and selective ALIGATER gene delivery platform. We are confident that this technology will allow us to generate a pipeline of transformative gene therapy products for the treatment of rare ocular and CNS indications," Rodolphe Clerval, Coave Therapeutics CEO.